SS

Selvaraj Silambarasan

Active Director Designated Partner DIN 11007081
DIN 11007081 First appointment Mar 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Selvaraj Silambarasan

Data last updated:

Selvaraj Silambarasan is a Designated Partner at Medorise Pharma Llp (since 2025).

DIN 11007081
Primary Designation Designated Partner
First Appointment 19 Mar 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner19 Mar 20252025Active

Board colleagues of Selvaraj Silambarasan

NameDINCompanyDesignation
Anand11007079Medorise Pharma LlpDesignated Partner
Kannadasan Gurunathan11007080Medorise Pharma LlpDesignated Partner
Krishnan Baskaran11007078Medorise Pharma LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Medorise Pharma Llp
Premium access

Shareholding and investment profile for Selvaraj Silambarasan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Selvaraj Silambarasan

Selvaraj Silambarasan currently holds 1 directorship: Medorise Pharma Llp (Designated Partner, since 19 Mar 2025).

Selvaraj Silambarasan was first appointed on 19 Mar 2025 as Designated Partner at Medorise Pharma Llp.

The current boards of Selvaraj Silambarasan's companies include Anand (Medorise Pharma Llp), Kannadasan Gurunathan (Medorise Pharma Llp), Krishnan Baskaran (Medorise Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available